Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
about
Calsequestrin 2 and arrhythmiasNon-pharmacological modulation of the autonomic tone to treat heart failureDisease modeling and cell based therapy with iPSC: future therapeutic option with fast and safe applicationChannel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular CardiomyocytesPatient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular TachycardiaCurrent topics in catecholaminergic polymorphic ventricular tachycardiaFlecainide: Current status and perspectives in arrhythmia managementCalsequestrin mutations and catecholaminergic polymorphic ventricular tachycardiaTherapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockersNeuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release.Novel pharmacological targets for the rhythm control management of atrial fibrillation.Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ releaseCarvedilol analogue inhibits triggered activities evoked by both early and delayed afterdepolarizationsRyanodine receptor inhibition potentiates the activity of Na channel blockers against spontaneous calcium elevations and delayed afterdepolarizations in Langendorff-perfused rabbit ventricles.In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current.Parameter sensitivity analysis of stochastic models provides insights into cardiac calcium sparks.Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts.Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.Novel molecular targets for atrial fibrillation therapy.Calcium handling and atrial fibrillation.Themes and variations in ER/SR calcium release channels: structure and function.New directions in antiarrhythmic drug therapy for atrial fibrillation.Electrical storm: recent pathophysiological insights and therapeutic consequences.Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.Pharmacotherapy for inherited arrhythmia syndromes: mechanistic basis, clinical trial evidence and practical application.Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.Advances in the pharmacologic treatment of ventricular arrhythmias.Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.Murine Electrophysiological Models of Cardiac Arrhythmogenesis.Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.Therapeutic Strategies Targeting Inherited Cardiomyopathies.Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor.Plakophilin-2 is required for transcription of genes that control calcium cycling and cardiac rhythm.Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia.
P2860
Q24300626-ED1CDE71-4AF8-4184-846B-B754F5EE1603Q26822899-BB4CBB76-E029-4106-848E-4BF9828E6CF6Q26866409-CDD8BEC1-7722-46D0-A7FC-9EE4C9EF6150Q27303698-52284169-324B-4366-B035-05B2385A38D6Q28067569-A06EC6F1-6411-40D3-A52F-89F48AC83100Q28076784-6BA22BA4-C49E-43A4-8BC9-0D041B8F307BQ28081935-7A32C04D-4F06-4526-A416-5122AE5BFEE9Q28262015-B23C9469-D9D7-4BA0-A1FA-F7808E6A2772Q33160416-D18794FB-3D3B-41B0-9037-5157F80EEF46Q33167418-9A7CC06C-6C50-48B3-B70D-0939BC9227C8Q34482842-415F9AB1-4D31-44A4-A327-CBF3B8BD2584Q35110915-ACAB6619-F7C0-40B5-A3F5-F150C40E4BBEQ35221369-D82C444A-8F7B-4525-A3A2-9B468D18900DQ35489060-51C95DB2-2A97-402A-B426-5E8D18F8C7D0Q35707246-F7860A60-8D1E-4235-B0B6-C5C356190DF3Q36501298-B41B07FE-FD4B-4AD4-84E8-D83D255A787FQ36610682-C058314E-4793-4F85-A2A4-838152235BA5Q36667578-2DDF2A35-F34E-4F99-AEEA-A9187A3C7391Q36696236-0D04571A-3ACA-4E39-957A-EA47EAECE80DQ37023408-CB42419A-1865-4D7A-B42F-77262EAE246CQ37409658-BE1E336F-FF26-4D97-BC2F-4063FF3A8279Q37707108-8BC750D8-112F-49FA-9DAE-F16263500874Q37708601-E8FCBDA0-C54F-408F-B38C-1EA85D10BC29Q37998312-FC647C42-14DE-41E8-81AF-BCC0B11137F2Q38018509-A619E0AF-BABE-45F3-B0F2-9685B7DDA9D8Q38065938-6D2B9958-D28A-433F-9F8A-2410008CB14DQ38069201-4AF1E0FD-120F-4CED-95D1-8688EC47642EQ38083549-9EA2E6F2-BA65-43C6-AFC2-57AD13FA0903Q38376971-D0BF7903-118F-4DBE-8AD9-8DB5E8FE63D1Q38494265-991AA543-B49A-4356-AE61-5DF3C6C84492Q38602828-BAD8D95C-EC9B-465D-9B44-46D23B4E4B3BQ38619253-8EACCDEC-F53D-46E5-A416-B04C835F48DFQ39022381-EB061752-C78A-4D0E-B1F6-6CF1D98D9503Q39038606-00F5AB2D-1CFD-4250-990D-7F74DA83205CQ39215625-AE523311-B7DD-4549-8705-D8401810EE44Q39404059-23579E23-415B-402C-8642-B59B36B7737EQ39727420-D72A4A36-D4A5-4E52-9FA8-A3EFA2B1957EQ41107820-CA9D1AD5-2245-425B-ABBB-D0A17BB303E7Q41910718-CEFD1782-A59C-475E-BD06-6D5402DAC4F4Q43158949-696BCDBF-5AA3-44CB-9382-74E5445B8A6D
P2860
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Inhibition of cardiac Ca2+ rel ...... rphic ventricular tachycardia.
@ast
Inhibition of cardiac Ca2+ rel ...... rphic ventricular tachycardia.
@en
Inhibition of cardiac Ca2+ release channels
@nl
type
label
Inhibition of cardiac Ca2+ rel ...... rphic ventricular tachycardia.
@ast
Inhibition of cardiac Ca2+ rel ...... rphic ventricular tachycardia.
@en
Inhibition of cardiac Ca2+ release channels
@nl
prefLabel
Inhibition of cardiac Ca2+ rel ...... rphic ventricular tachycardia.
@ast
Inhibition of cardiac Ca2+ rel ...... rphic ventricular tachycardia.
@en
Inhibition of cardiac Ca2+ release channels
@nl
P2093
P2860
P1476
Inhibition of cardiac Ca2+ rel ...... orphic ventricular tachycardia
@en
P2093
Can Hasdemir
Derek Laver
Divya Mehra
Huiyong Yin
Hyun Seok Hwang
Kutsal Turhan
Michela Faggioni
P2860
P304
P356
10.1161/CIRCEP.110.959916
P577
2011-01-26T00:00:00Z